Smell Disorders as Neurological Indicators: Current Evidence and Therapeutic Advances

Abstract

Olfactory dysfunction, often underrecognized in clinical practice, has emerged as a critical marker for neurological health and disease. This review synthesizes contemporary research on the epidemiology, pathophysiology, risk factors, clinical presentation, diagnostic strategies, and management of olfactory impairment, with a focus on its relationship to brain health. The article explores the mechanistic links between olfactory deficits and neurodegenerative disorders, highlights recent advances in therapeutic interventions, and summarizes current guideline-based recommendations for clinicians. Understanding the intricate interplay between olfaction and central nervous system integrity has direct implications for early diagnosis, risk stratification, and multidisciplinary management of patients at risk for or living with neurodegenerative diseases.

Introduction

Olfactory dysfunction, defined as a partial (hyposmia) or complete (anosmia) loss of smell, is gaining recognition for its strong association with neurodegenerative diseases and overall brain health. While traditionally overshadowed by other sensory deficits, olfactory impairment is increasingly viewed as an early biomarker for conditions such as Parkinson’s disease, Alzheimer’s disease, and other dementias. The olfactory system’s unique anatomical connections to limbic and cortical brain regions underscore its pivotal role in both sensory perception and cognitive function. This article critically reviews the current landscape of olfactory dysfunction, its clinical relevance, and the implications for practitioners managing patients at risk for or presenting with central nervous system disorders.

Epidemiology / Disease Burden

Olfactory dysfunction affects approximately 3–20% of the general population, with prevalence rising sharply with age. Population-based studies report that up to 60% of individuals over 65 may experience some degree of olfactory loss. The burden is further amplified by its association with chronic neurological disorders: up to 90% of Parkinson’s disease patients and 85% of those with Alzheimer’s exhibit olfactory deficits, often preceding classical motor or cognitive symptoms by years. Beyond neurodegeneration, olfactory disturbances can result from upper respiratory infections, sinonasal disease, traumatic brain injury, and systemic illnesses, contributing to significant morbidity, impaired quality of life, nutritional deficits, and increased mortality risk in affected populations.

Pathophysiology

The olfactory system is uniquely vulnerable to both peripheral and central insults. At the peripheral level, damage to the olfactory epithelium or olfactory nerve fibers can result from viral infections, toxins, or trauma. Centrally, olfactory dysfunction reflects pathology in the olfactory bulb, tract, or higher-order cortical areas, particularly the entorhinal cortex, piriform cortex, and orbitofrontal cortex. Neurodegenerative processes such as α-synuclein accumulation in Parkinson’s disease and β-amyloid/tau pathology in Alzheimer’s disease disrupt olfactory signaling pathways early in the disease course. The bidirectional relationship between olfactory impairment and neuroinflammation, blood-brain barrier dysfunction, and synaptic degeneration further elucidates its role as a harbinger of broader cerebral pathology.

Risk Factors

Major risk factors for olfactory dysfunction include advanced age, male sex, history of chronic rhinosinusitis, upper respiratory viral illnesses (notably post-viral anosmia following COVID-19 infection), traumatic brain injury, chronic exposure to environmental toxins (solvents, pesticides), and genetic predispositions. Neurological comorbidities especially Parkinson’s disease, Alzheimer’s disease, Lewy body dementia, and multiple sclerosis significantly increase risk. Additional contributors include tobacco smoking, metabolic syndrome, and certain medications (e.g., antihypertensives, antibiotics, chemotherapeutics) which may impair olfactory neurogenesis or disrupt mucosal integrity.

Clinical Features

Patients with olfactory dysfunction typically present with reduced or absent ability to detect, identify, or discriminate odors. This may manifest as diminished flavor perception, unintentional weight loss, decreased appetite, or exposure to environmental hazards (e.g., spoiled food, gas leaks). In neurodegenerative contexts, olfactory impairment often precedes classic motor or cognitive symptoms by several years, serving as a prodromal indicator. Associated non-motor features may include depressive symptoms, social withdrawal, and impaired quality of life. Detailed clinical history and symptom chronology are essential for differentiating peripheral from central etiologies.

Diagnosis

Diagnosis of olfactory dysfunction relies on a combination of clinical assessment and standardized olfactory testing. Objective measures include the University of Pennsylvania Smell Identification Test (UPSIT), Sniffin’ Sticks, and Brief Smell Identification Test (BSIT), which quantify detection, threshold, discrimination, and identification capacities. Neuroimaging, such as MRI, may reveal olfactory bulb atrophy or signal changes in central olfactory processing areas, particularly in neurodegenerative disease. Ancillary investigations include endoscopic evaluation of the nasal cavity for local pathology, and laboratory screening for reversible metabolic or endocrine causes. Early identification is crucial, as it provides an opportunity for risk stratification and timely intervention in neurodegenerative disorders.

Treatment & Management

Treatment of olfactory dysfunction is tailored to the underlying etiology. For sinonasal or post-infectious causes, corticosteroid therapy (intranasal or systemic) and olfactory training (repetitive exposure to a panel of distinct scents) have shown efficacy in randomized trials. Management of neurodegenerative-associated olfactory loss remains largely supportive, focusing on patient education, nutritional counseling, and safety precautions. Addressing modifiable risk factors such as cessation of smoking, avoidance of neurotoxins, and optimizing comorbid conditions may delay progression. Psychological support and referral to specialized olfactory clinics are recommended for persistent or severe cases.

Recent Advances / Emerging Therapies

Recent years have seen promising developments in olfactory rehabilitation and neuroregenerative therapies. Olfactory training protocols have demonstrated neuroplastic changes in the olfactory bulb and related cortical regions, with clinical improvements in both idiopathic and post-viral anosmia. Investigational therapies include intranasal delivery of neurotrophic factors, stem cell transplantation, and transcranial direct current stimulation targeting olfactory-related brain regions. Advances in molecular imaging and biomarkers are enhancing early detection of neurodegenerative disease in olfactory-impaired individuals. Moreover, the COVID-19 pandemic has catalyzed research into viral-induced olfactory loss and its long-term neurological sequelae, highlighting the need for ongoing surveillance and innovation in this field.

Guideline Recommendations

Current clinical guidelines emphasize systematic evaluation of new-onset olfactory dysfunction, particularly in adults over 50 or those with neurological risk factors. Early use of validated olfactory testing, coupled with neuroimaging in atypical or rapidly progressive cases, is advocated. For post-infectious or idiopathic anosmia, olfactory training is recommended as first-line therapy, with adjunct corticosteroids considered on a case-by-case basis. In patients with established neurodegenerative disease, routine olfactory assessment can aid in risk stratification and care planning. Interdisciplinary management including otolaryngology, neurology, nutrition, and mental health support is essential for optimizing outcomes and quality of life.

Conclusion

Olfactory dysfunction is a prevalent and clinically significant marker of brain health, offering a window into early neurodegenerative processes and systemic disease. Advances in diagnostic testing and rehabilitation strategies have enhanced the clinician’s ability to detect, characterize, and manage olfactory loss in diverse patient populations. Ongoing research into the mechanisms linking olfaction and central nervous system integrity holds promise for novel therapeutic targets and improved prognostication. Vigilance in olfactory assessment and adherence to evidence-based guidelines can facilitate earlier diagnosis, intervention, and multidisciplinary care, ultimately improving patient outcomes in the context of neurodegenerative disease and beyond.